A detailed history of Raymond James & Associates transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 38,825 shares of XLO stock, worth $34,166. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,825
Previous 38,825 -0.0%
Holding current value
$34,166
Previous $36,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$0.9 - $1.53 $34,942 - $59,402
38,825 New
38,825 $36,000

Others Institutions Holding XLO

About Xilio Therapeutics, Inc.


  • Ticker XLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,471,600
  • Market Cap $24.2M
  • Description
  • Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...
More about XLO
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.